One Biosciences Advances with €15 Million Series A Funding
Deal News | Jul 17, 2025 | PR Newswire Cision One Biosciences
One Biosciences, a precision oncology company based in Paris, has raised €15 million in Series A funding led by Redmile Group and Blast, with additional investments from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. The company will use the funds to enhance its AI-driven single-cell transcriptomic oncology platform, OneMap™, which aids in cancer treatment decisions, patient selection, and optimizing clinical trials. The investment will also allow One Biosciences to scale its strategic partnerships with pharmaceutical and biotech companies. Established in 2020, One Biosciences is at the forefront of clinical-grade single-cell tumor transcriptomic profiling, an approach that offers potential improvements in personalized cancer treatments. Co-founded by Dr. Céline Vallot, One Biosciences is supported by various institutions including Curie Institute and has collaborations with several scientific and medical entities. After this financial boost, the company’s total funding surpasses €20 million.
Sectors
- Biotechnology
- Healthcare
- Artificial Intelligence
Geography
- France – One Biosciences is based in Paris, France, and collaborates with various French institutes.
- Europe – The investment and collaboration network extend throughout Europe, involving several European venture partners and institutions.
Industry
- Biotechnology – The article is centered around One Biosciences, a biotechnology firm focusing on cancer treatment through AI-driven single-cell transcriptomic profiling.
- Healthcare – The company's efforts in cancer diagnostics and treatment place it within the healthcare sector, aiming to revolutionize oncology.
- Artificial Intelligence – One Biosciences employs AI to advance their single-cell profiling technology, highlighting the integration of AI in modern healthcare solutions.
Financials
- €15,000,000 – Total Series A financing amount raised by One Biosciences.
- €20,000,000+ – Total funding raised by One Biosciences to date, including seed financing.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| One Biosciences | Target Company | Company | A Paris-based precision oncology company specializing in AI-driven single-cell profiling technology. |
| Redmile Group | Lead Investor | Company | A global investment organization leading the Series A financing for One Biosciences. |
| Blast | Investor | Company | An investment firm participating in the financing round for One Biosciences. |
| Galion.exe | Investor | Company | An investment firm involved in One Biosciences' funding. |
| Invus | Investor | Company | Participated in the funding round for One Biosciences. |
| Adamed Technology | Investor | Company | Another investor in the Series A funding for One Biosciences. |
| Sofinnova Partners | Investor | Company | A European venture capital firm investing in life sciences, participating in One Biosciences' funding. |
| Polytechnique Ventures | Investor | Company | An investor in the financing for One Biosciences. |
| Kima Ventures | Investor | Company | A global venture capital firm participating in the funding round. |
| Hedi Ben Brahim | CEO | Person | CEO of One Biosciences, overseeing the company's strategic direction. |
| Dr. Céline Vallot | Co-Founder | Person | Co-Founder of One Biosciences and group leader at Curie Institute. |
| Dr Mehdi Touat | Assistant Professor | Person | Assistant Professor at Assistance Publique - Hôpitaux de Paris and Paris Brain Institute. |
| Curie Institute | Partner | Organization | A partner organization collaborating with One Biosciences. |
| AP-HP | Partner | Organization | Partner in collaborative efforts with One Biosciences. |
| Home Biosciences | Founding Investor | Company | Provided seed funding for One Biosciences, integral in its establishment. |